



Reassessment of subscription price for Lumito TO1 subscription warrants

According to the terms and conditions for series Lumito TO1 subscription warrants, the subscription price shall be reassessed under certain conditions, such as when a preferential rights issue takes place during the warrant life of Lumito TO1.

Since Lumito has recently conducted a preferential rights issue, the subscription price for LUMITO TO1 has been reassessed according to the warrant terms. Originally, each LUMITO TO1 subscription warrant entitled the holder to the subscription of one share at a subscription price of SEK 7.00. The reassessment due to the conducted preferential rights issue entails that each subscription warrant now carries the right to subscribe for 1.32 shares, at a subscription price of SEK 5.31.

For more information contact:

Lumito AB (publ), CEO Stefan Nilsson, telefon +46 767 78 59 05, sn@lumito.se

Lumito in brief

Lumito is specialised in research and development of imaging technologies for medical applications. The technology is based on so called UCNP:s (Up Converting Nano Particles) and is aiming to increase image quality in biomedical applications. Lumito's IPR covers imaging with high quality of for instance tissue samples, with UCNP:s as markers. The technology has several possible application areas, but Lumito has initially decided to focus on digital pathology. Lumito has an agreement with TTP plc (The Technology Partnership) in Cambridge, UK, regarding development of instruments and staining reagents. Lumito's share Lumito and warrant Lumito TO1 are traded at the NGM Nordic MTF marketplace.